Publication | Closed Access

A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients

HepatologyHepatitis CViral HepatitisAntiviral ActivityImmunologyAntiviral Drug DevelopmentHepatitisVirologyAntiviral TherapyAntiviral ResponseAntiviral DrugPhase 2MedicineGenotype 1